Monograph Details
|
|
Neoplasms
> Hormones and antagonists
|
|
VANTAS |
| Manufacturer |
|
Valera Pharmaceuticals, Inc. |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
GnRH analogue. |
| Generic Name |
|
Histrelin acetate 50mg; SC implant. |
| Indications |
|
Palliative treatment of advanced prostate cancer. |
| Children |
|
Not applicable. |
| Adults |
|
Insert 1 implant SC in the inner aspect of the upper arm. Remove after 12 months; may replace. |
| Contraindications |
|
Pregnancy (Cat.X). Nursing mothers. Not for use in women or children. |
| Precautions |
|
Metastatic vertebral lesions, urinary tract obstruction (monitor closely in 1st few weeks). Avoid wetting inserted arm for 24 hrs and heavy lifting or strenuous exertion for 1st week. Monitor testosterone, PSA levels. Implant not visible on X-ray. |
| Interactions |
|
May interfere with pituitary gonadotropic and gonadal function tests. |
| Adverse Reactions |
|
Hot flashes, initial worsening of signs/symptoms (eg, bone pain, urinary tract obstruction, hematuria), fatigue, increased weight, local reactions, CNS or antiandrogenic effects, renal impairment, constipation, headache. |
| How Supplied |
|
Kit—1 (w. implant and supplies) |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
